Catalent Inc (NYSE:CTLT) – Equities researchers at William Blair raised their FY2018 earnings estimates for shares of Catalent in a note issued to investors on Wednesday, Zacks Investment Research reports. William Blair analyst J. Kreger now anticipates that the company will post earnings of $1.52 per share for the year, up from their prior estimate of $1.43. William Blair also issued estimates for Catalent’s Q4 2018 earnings at $0.63 EPS, Q2 2019 earnings at $0.38 EPS, Q3 2019 earnings at $0.45 EPS, Q4 2019 earnings at $0.67 EPS and FY2019 earnings at $1.76 EPS.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, February 5th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. During the same period last year, the company earned $0.27 EPS. Catalent’s revenue for the quarter was up 25.3% on a year-over-year basis.
Several other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Catalent from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Royal Bank of Canada started coverage on Catalent in a research note on Wednesday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Piper Jaffray Companies boosted their price target on Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. BidaskClub downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Finally, ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $45.20.
Catalent (NYSE CTLT) traded down $3.10 during midday trading on Friday, reaching $43.50. The company had a trading volume of 2,355,965 shares, compared to its average volume of 841,957. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87. The company has a market cap of $6,191.25, a P/E ratio of 50.00, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49.
In other news, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Uwe Roehrhoff acquired 7,500 shares of the stock in a transaction dated Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, for a total transaction of $294,150.00. The disclosure for this purchase can be found here. 1.70% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zions Bancorporation purchased a new position in Catalent in the 3rd quarter worth approximately $100,000. Acrospire Investment Management LLC lifted its holdings in Catalent by 72.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after purchasing an additional 1,300 shares in the last quarter. Quantbot Technologies LP lifted its holdings in Catalent by 110.7% in the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after purchasing an additional 1,804 shares in the last quarter. First Bank & Trust lifted its holdings in Catalent by 54.2% in the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after purchasing an additional 1,323 shares in the last quarter. Finally, Fortaleza Asset Management Inc. purchased a new position in Catalent in the 3rd quarter worth approximately $164,000. 98.86% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “William Blair Comments on Catalent Inc’s FY2018 Earnings (CTLT)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/fy2018-earnings-estimate-for-catalent-inc-ctlt-issued-by-william-blair.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.